By Fineline Cube 
Kailera Therapeutics, Inc., the Delaware‑registered spin‑off of Hengrui Pharma, today announced the closing of a fully funded $600 million Series B financing round led by Bain Capital Private Equity. The capital injection will underpin the company’s global Phase III program for its lead obesity candidate KAI‑9531, an injectable dual GLP‑1/GIP receptor agonist, and will propel the next‑generation oral GLP‑1 agonist KAI‑7535 into worldwide clinical development.
Funding Snapshot
| Item | Details |
|---|---|
| Investor | Bain Capital Private Equity (lead) |
| Capital Raised | $600 million (Series B) |
| Use of Proceeds | 1) Phase III global trial of KAI‑9531 (injectable) 2) Phase III global rollout of KAI‑7535 (oral) 3) Early‑stage programs (KAI‑4729, oral KAI‑9531) 4) Strategic asset development & licensing rights |
| Equity Stake | Bain Capital will hold a minority equity position; Hengrui retains 19.9 % ownership |
Pipeline Highlights
| Candidate | Status | Clinical Milestone |
|---|---|---|
| KAI‑9531 | Lead obesity drug | Global Phase III trial (injectable dual GLP‑1/GIP agonist) – “best‑in‑category” weight‑loss profile |
| KAI‑7535 | Oral GLP‑1 agonist | Transitioning to global Phase III after Phase II success in China |
| KAI‑4729 | Tri‑agonist (GLP‑1/GIP/Glucagon) | Early‑stage development |
| Oral KAI‑9531 | Once‑daily tablet | Formulation and clinical testing underway |
Kailera also holds rights to new formulations of licensed products and first‑refusal options on selected assets from Hengrui Pharma’s broader metabolic‑disease portfolio.
Strategic Implications
- Capital Leverage – The $600 million infusion positions Kailera to complete its global obesity program ahead of competitors in the rapidly expanding GLP‑1 market.
- Investor Confidence – Bain Capital’s partnership signals strong validation of Kailera’s science and growth trajectory.
- Portfolio Expansion – Rights to additional Hengrui assets provide a diversified pipeline and potential revenue streams beyond obesity.
About Kailera Therapeutics
Founded in May 2024 and incorporated in Delaware, Kailera Therapeutics is the exclusive global developer and commercializer of four Hengrui‑licensed metabolic disease assets outside Greater China. Hengrui Pharma (SHA: 600276, \) maintains a 19.9 % equity stake.
Forward‑Looking Statements
This release contains forward‑looking statements regarding future performance, product development, and regulatory approvals. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially.-Fineline Info & Tech